Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03695978 · ClinicalTrials.gov registry record
Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
A clinical trial of Haemophilia A, sponsored by Octapharma.
- Recruiting
- Registry status
- 200
- Enrollment target
- 20
- Study locations
NCT03695978: Recruiting study of Haemophilia A, sponsored by Octapharma.
NCT03695978 is a study of Haemophilia A that is actively recruiting participants, run by Octapharma. The registered enrollment target is 200 participants, roughly in line with the 200-participant average among 8 other Haemophilia A trials with a reported enrollment target. The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03695978, a study of Haemophilia A, is actively recruiting participants, sponsored by Octapharma.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
International, post-authorisation non-interventional study to evaluate real-life effectiveness, safety and utilisation patterns of Octapharma's FVIII concentrates Nuwiq, Octanate, and Wilate in previously untreated and minimally treated severe haemophilia A patients in routine clinical practice.
Primary Outcome
Annualised rate of all bleeding events (BEs), including all spontaneous, traumatic and joint BEs
Conditions Studied
Study Locations (20)
Other
- CENIDOR - Salta
- Azerbaijan State Advanced Training Institute for Doctors Hematology Department Scientific-Research Center of Hemophilia - Baku
- Republican Scientific Center for Radiation Medicine and Human Ecology - Homyel
- Republican Scientific and Practical Centre of Children Oncology, Hematology and Immunology - Minsk
- Hôpital Universitaire des Enfants Reine Fabiola - Brussels
- Cliniques Universitaires Saint-Luc - Brussels
- Cliniques Universitaires Saint-Luc - Brussels
- Department of Hematology Research Research Transition Facility - Edmonton
- University Hospital Centre Zagreb - Zagreb
- Tallinn Childrenś Hospital Clinic of Paediatric Department of Haematology and Oncology - Tallinn
- CENTRE HOSPITALIER UNIVERSITAIRE de BESANCON - Besançon
- CHRU Tours - Hôpital Trousseau - Chambray-lès-Tours
- Centre Régional de Traitement de l'hémophilie - Le Mans
- Hopital Simone Veil Groupement Hospitalier Eaubonne-Montmorency - Montmorency
- CHU Hotel Dieu, Centre de Traitment de l'Hemophilie - Nantes
- Hôspital Necker Enfants Malades - Paris
Florida
- University of Miami Miller School of Medicine - Miami
Louisiana
- Ochsner Clinic Foundation - New Orleans
Nevada
- Cure 4 The Kids Foundation Children's Specialty Center - Las Vegas
Ontario
- McMaster University, Division of Pediatric Hematology/Oncology Room 3N27 - Hamilton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2018-02-13 |
| Est. Completion | 2030-06 |
What NCT03695978 shows while recruiting
NCT03695978 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 200-participant average among 8 other Haemophilia A trials with a reported enrollment target.
The record links to 1 condition, with Haemophilia A appearing as the primary indexed condition, and to 0 interventions.
NCT03695978 names 20 study sites across 5 states, led by Other, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT03695978 about?
NCT03695978 is a clinical study titled "Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients". International, post-authorisation non-interventional study to evaluate real-life effectiveness, safety and utilisation patterns of Octapharma's FVIII concentrates Nuwiq, Octanate, and Wilate in previously untreated and minimally treated severe haemophilia A patients in routine clinical practice.
What is the current status of trial NCT03695978?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2018-02-13. Estimated completion is 2030-06.
What conditions does trial NCT03695978 study?
This clinical trial studies the following conditions: Haemophilia A.
Who is sponsoring clinical trial NCT03695978?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03695978 being conducted?
This trial has 20 study locations across Florida, Louisiana, Nevada, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Haemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03695978's enrollment target sits among peer trials
200 4th of 8 higher than 5 of 8 other Haemophilia A trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Haemophilia A trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
RECRUITING · Phase 1
-
A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People
RECRUITING · Phase 1
-
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4)
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
COMPLETED · Phase 3
-
Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A
COMPLETED · Phase 3
-
A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI